Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, et al. Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. J Cancer Res Clin Oncol 2023;149:5493-5496.
PMID: 36469155